Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 first-line intensified chemotherapy strategy for metastatic Ewing tumor with extrapulmonary dissemination
2016-000981-46Phase 2Completed
- Sponsor
- Institut Curie
- Start
- Oct 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide and 6 more in Ewing sarcoma and bone cancer, sponsored by Institut Curie. Primary endpoint: 18-month event-free survival. Started Oct 2016; status: completed.
02
Drugs
vincristinedoxorubicincyclophosphamideifosfamideetoposide
03
Conditions
Ewing sarcomabone cancer
Beyond the preview
Go deeper on 2016-000981-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000981-46.